Novel targeted therapies for inflammatory bowel disease

Mehmet Coskun, Severine Vermeire, Ole Haagen Nielsen

77 Citationer (Scopus)

Abstract

Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.

OriginalsprogEngelsk
TidsskriftTrends in Pharmacological Sciences
Vol/bind38
Udgave nummer2
Sider (fra-til)127-142
Antal sider16
ISSN0165-6147
DOI
StatusUdgivet - 1 feb. 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'Novel targeted therapies for inflammatory bowel disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater